12:28 PM EDT, 03/11/2024 (MT Newswires) -- Bluebird bio (BLUE) said Monday that it signed its first Medicaid outcomes-based agreement for its Lyfgenia sickle cell disease gene therapy with Michigan state.

Lyfgenia is approved for the treatment of sickle cell patients at least 12 years old, with a history of vaso-occlusive events. Bluebird bio said its outcomes-based contract uses a claims-based metric related to clinical benefit, offering patients risk sharing in vaso-occlusive events-related hospitalizations.

Bluebird bio is also in talks for a deal with over 15 Medicaid agencies and has already signed several outcomes-based agreements for Lyfgenia with commercial payer organizations in the US.

Bluebird bio shares were down 6% in recent trading.

Price: 1.41, Change: -0.09, Percent Change: -6.00